Semaglutide

New Therapies in the Prevention of Cardiac Damage in Patientswith CKM Syndrome

by Prateek Chopra | June 3, 2026 | Cardiology Conferences | ESH 2026 Clinical Context: Cardiovascular-kidney-metabolic (CKM) syndrome encompasses overlapping progression of cardiovascular disease, chronic kidney disease, obesity, diabetes, and hypertension, resulting in persistent myocardial injury and increased heart failure risk. Contemporary management focuses on integrated therapies targeting cardio-renal-metabolic pathways to prevent progressive cardiac damage. Key Pathophysiology & Mechanisms: Emerging Therapeutic […]

New Therapies in the Prevention of Cardiac Damage in Patientswith CKM Syndrome Read Post »

Leave a Comment / ESH Day 1 / bluetree.healthcare@gmail.com / July 29, 2026 / Cardiorenal Protection, Cardiovascular-Kidney-Metabolic (CKM) Syndrome, Finerenone, Semaglutide, SGLT2 Inhibitors

Serum Proteomics Suggest Novel Mechanisms of Action of Semaglutide in Reducing the Risk of MACE in the SELECT Trial

by Prateek Chopra | July 5, 2026 | Diabetes Conferences | ADA 2026 Mechanistic Insights Methods Key Findings Protein-Specific Effects Clinical Implications Four circulating proteins—THBS2, NPPB, ANGPT2, and CD93—mediated a substantial proportion of semaglutide’s cardiovascular benefit independent of weight loss. These findings provide new insights into the biological mechanisms underlying semaglutide’s cardioprotective effects.

Serum Proteomics Suggest Novel Mechanisms of Action of Semaglutide in Reducing the Risk of MACE in the SELECT Trial Read Post »

Leave a Comment / Diabetes Conferences / bluetree.healthcare@gmail.com / July 29, 2026 / Cardiovascular Disease, GLP-1 Receptor Agonists, Major Adverse Cardiovascular Events (MACE), SELECT Trial, Semaglutide

Insights from the REIMAGINE Trial: Robust Glycaemic Control and Meaningful Weight Loss with Cagri Sema Across DiverseT2D Population

by Prateek Chopra | June 29, 2026 | Diabetes Conferences | ADA 2026 Therapy Overview REIMAGINE Trial Programme Glycemic Outcomes Weight Loss Outcomes Benefits in Insulin-Treated T2D Safety Profile Clinical Implications The REIMAGINE programme showed that CagriSema delivers substantial improvements in glycemic control and body weight across diverse T2D populations. Its consistent efficacy and favorable safety profile support its potential

Insights from the REIMAGINE Trial: Robust Glycaemic Control and Meaningful Weight Loss with Cagri Sema Across DiverseT2D Population Read Post »

Leave a Comment / Diabetes Conferences / bluetree.healthcare@gmail.com / July 29, 2026 / ADA 2026, CagriSema, GLP-1 Receptor Agonists, REIMAGINE Trial, Semaglutide, Type 2 Diabetes (T2DM)

Optimising Prescribing in Type 2 Diabetes: Updating a Five-Drug Class Treatment Selection Model to Include NewerGLP-1 Receptor Agonists

by Prateek Chopra | June 29, 2026 | Diabetes Conferences | ADA 2026 Precision Medicine in T2D Methods Study Population Model Performance Key Findings Clinical Implications The updated five-drug class prediction model accurately predicts HbA1c responses to both oral and subcutaneous semaglutide. Successful external validation supports its use as a precision medicine tool for individualized treatment selection in type 2

Optimising Prescribing in Type 2 Diabetes: Updating a Five-Drug Class Treatment Selection Model to Include NewerGLP-1 Receptor Agonists Read Post »

Leave a Comment / Diabetes Conferences / bluetree.healthcare@gmail.com / July 29, 2026 / ADA 2026, GLP-1 Receptor Agonists, Personalized Diabetes Treatment, Precision Medicine, Semaglutide, Type 2 Diabetes (T2DM)